With the growth in understanding of the importance of cytochrome P450 2D6 (CYP2D6) polymorphism and its relationship with the therapeutic outcome of tamoxifen in patients with breast cancer [6], we can now partly attribute the unpredictable results from early melanoma studies to CYP2D6 polymorphism [7]. The gene discussed is CYP2D6; the disease is breast cancer.